NEW YORK (GenomeWeb News) — Enzyme developer Dyadic International today said it has generated around $12.6 million in a private stock placement.
 
Dyadic said it will use roughly $12.3 million of the placement to expand its C1 Host Technology, which is used in the production of biomass production, and potentially in human antibody and therapeutic protein production.
 
The company also plans to use some funds to speed up the launch of new enzyme products, R&D and marketing.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.